Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N9HB | ISIN: CA25253X2077 | Ticker-Symbol: F2KA
NASDAQ
06.06.25 | 21:57
4,155 US-Dollar
+1,09 % +0,045
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DIAMEDICA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DIAMEDICA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DIAMEDICA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.05.H.C. Wainwright holds DiaMedica stock Buy rating, $10 target1
14.05.DiaMedica Therapeutics Inc.: DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference - ESOC 2025288DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today a poster presentation of...
► Artikel lesen
14.05.DiaMedica targets preeclampsia Phase 2 dose selection and ReMEDy2 interim analysis in H1 2026 as enrollment momentum builds2
14.05.DiaMedica Therapeutics GAAP EPS of -$0.18 in-line5
13.05.DiaMedica Therapeutics Inc. - 10-Q, Quarterly Report1
DIAMEDICA THERAPEUTICS Aktie jetzt für 0€ handeln
13.05.DiaMedica Therapeutics Inc. - 8-K, Current Report1
12.05.Insights Ahead: DiaMedica Therapeutics' Quarterly Earnings1
17.03.DiaMedica Therapeutics GAAP EPS of -$0.60 misses by $0.011
17.03.DiaMedica Therapeutics Inc. - 10-K, Annual Report1
17.03.DiaMedica Therapeutics Inc. - 8-K, Current Report1
06.03.DiaMedica Therapeutics Inc. - 8-K, Current Report-
24.02.DiaMedica Therapeutics Inc. - 8-K, Current Report-
24.02.DiaMedica gewinnt neues Vorstandsmitglied mit Führungserfahrung in der Biopharma-Branche2
24.02.DiaMedica welcomes new board member with biopharma leadershi1
13.11.24DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results117MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided...
► Artikel lesen
09.10.24DiaMedica Therapeutics Inc.: DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia398Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage...
► Artikel lesen
07.08.24DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results156MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1